Who are Gammaplex 10's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gammaplex (5%), PRIVIGEN (CSL Behring), IgPro, Asceniv™, Flebogamma 5% DIF, Octagam (IVIG).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gammaplex-10.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gammaplex 10 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gammaplex 10 (Gammaplex 10) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IVIG). Area: Immunology.

phase 3 Intravenous immunoglobulin (IVIG) Fc receptors; pathogenic antibodies and antigens (non-specific) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Gammaplex 10 (Gammaplex 10) — Bio Products Laboratory. Gammaplex 10 is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gammaplex 10 TARGET	Gammaplex 10	Bio Products Laboratory	phase 3	Intravenous immunoglobulin (IVIG)	Fc receptors; pathogenic antibodies and antigens (non-specific)
Gammaplex (5%)	Gammaplex (5%)	Bio Products Laboratory	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors and complement system (indirect mechanism via antibody delivery)
PRIVIGEN (CSL Behring)	PRIVIGEN (CSL Behring)	Hospices Civils de Lyon	marketed	Intravenous immunoglobulin (IVIg)	Fc receptors, complement system, pathogenic antigens and antibodies
IgPro	IgPro	CSL Behring	marketed	Intravenous immunoglobulin (IVIG)	Multiple pathogenic antigens (polyvalent)
Asceniv™	Asceniv™	ADMA Biologics, Inc.	marketed	Intravenous immunoglobulin (IVIG)	Polyclonal immunoglobulins (IgG)
Flebogamma 5% DIF	Flebogamma 5% DIF	Instituto Grifols, S.A.	marketed	Intravenous immunoglobulin (IVIG)	Fc receptors, pathogenic antigens and antibodies
Octagam (IVIG)	Octagam (IVIG)	Oslo University Hospital	phase 3	Intravenous immunoglobulin (IVIG)	Multiple (polyvalent IgG; Fc receptors, complement system)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gammaplex 10 — Competitive Intelligence Brief. https://druglandscape.com/ci/gammaplex-10. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing